[go: up one dir, main page]

GT200600126A - Oblea que contiene hormonas estoides - Google Patents

Oblea que contiene hormonas estoides

Info

Publication number
GT200600126A
GT200600126A GT200600126A GT200600126A GT200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A
Authority
GT
Guatemala
Prior art keywords
hormones
steroid
stioid
oblea
almidon
Prior art date
Application number
GT200600126A
Other languages
English (en)
Inventor
Markus Krume
Sascha General
Albert Radlmaier
Michael Dittgen
Keith Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600126A publication Critical patent/GT200600126A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE AL SISTEMA DE APLICACION EN FORMA DE PELICULA PARA LA ADMINISTRACION TRANSMUCOSA DE UNA HORMONA ESTEROIDE. DONDE LA MEMBRANA ESTEROIDE PUEDE SER: TESTOSTERONA, 7-ALFA-METIL-19-NORTESTOSTERONA (MENT) O 7-ALFA-METIL-11-BETA-FLUORO-19-NORTESTOSTERONA (EF-MENT), ESTROGENO O MEZCLAS DE HORMONAS ESTEROIDES COMBINADAS CON UN MATERIAL DE SOPORTE. EL MATERIAL DE SOPORTE PUEDE SER: CELULOSA, DERIVADOS DE CELULOSA, POLI-N-VINILPIRROLIDONA, COPOLIMEROS DE VINILPIRROLIDONA-ACETATO DE FENILO, ALMIDON, DERIVADOS DE ALMIDON, GELATINA Y/O COADYUVANTES LIQUIDOS QUE AYUDAN A DISOLVER LA HORMONA ESTEROIDE
GT200600126A 2005-03-31 2006-03-27 Oblea que contiene hormonas estoides GT200600126A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone

Publications (1)

Publication Number Publication Date
GT200600126A true GT200600126A (es) 2007-03-14

Family

ID=36998911

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600126A GT200600126A (es) 2005-03-31 2006-03-27 Oblea que contiene hormonas estoides

Country Status (26)

Country Link
US (2) US9763960B2 (es)
EP (1) EP1863444B1 (es)
JP (2) JP5843416B2 (es)
KR (2) KR20140063740A (es)
CN (2) CN104983669B (es)
AR (1) AR054245A1 (es)
AU (1) AU2006228820B2 (es)
BR (1) BRPI0609601A2 (es)
CA (1) CA2598892C (es)
CR (1) CR9468A (es)
DE (1) DE102005015128B4 (es)
DO (1) DOP2006000070A (es)
EA (1) EA014183B1 (es)
GT (1) GT200600126A (es)
IL (1) IL186081A0 (es)
MX (1) MX2007012081A (es)
NO (1) NO20075404L (es)
NZ (1) NZ592882A (es)
PE (1) PE20061194A1 (es)
SG (1) SG179459A1 (es)
SV (1) SV2008002466A (es)
TW (1) TWI393576B (es)
UA (1) UA92011C2 (es)
UY (1) UY29441A1 (es)
WO (1) WO2006102990A2 (es)
ZA (1) ZA200706116B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2985026T3 (da) 2005-04-15 2022-10-31 Clarus Therapeutics Inc Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
NZ587309A (en) * 2008-02-13 2012-09-28 Bayer Schering Pharma Ag Wafer film systems for for the delivery of estrogen or progestin
EA201001245A1 (ru) * 2008-02-13 2011-04-29 Байер Шеринг Фарма Акциенгезельшафт Содержащая эстрадиол система доставки лекарственного средства
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
KR20110097779A (ko) * 2008-11-21 2011-08-31 바이엘 파마 악티엔게젤샤프트 약물 전달 시스템
CA2777218C (en) 2009-10-30 2016-09-27 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
EP3710012B1 (en) * 2018-02-02 2025-06-11 Acerus Biopharma Inc. Methods of testosterone therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
ES2105262T3 (es) * 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
CN1441669A (zh) * 2000-07-06 2003-09-10 德尔西斯药品公司 配制稳定性增强的保健产品的方法
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
BRPI0414551B8 (pt) * 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo

Also Published As

Publication number Publication date
TWI393576B (zh) 2013-04-21
KR20140063740A (ko) 2014-05-27
EP1863444A2 (de) 2007-12-12
CR9468A (es) 2008-01-21
KR101428625B1 (ko) 2014-08-13
CN104983669A (zh) 2015-10-21
DOP2006000070A (es) 2007-08-15
WO2006102990A2 (de) 2006-10-05
UY29441A1 (es) 2006-10-31
UA92011C2 (ru) 2010-09-27
AU2006228820B2 (en) 2011-08-25
CA2598892A1 (en) 2006-10-05
NZ592882A (en) 2012-12-21
CA2598892C (en) 2014-10-14
AR054245A1 (es) 2007-06-13
ZA200706116B (en) 2008-11-26
EP1863444B1 (de) 2015-12-09
CN104983669B (zh) 2018-05-18
PE20061194A1 (es) 2006-11-23
KR20080002798A (ko) 2008-01-04
US20170348321A1 (en) 2017-12-07
MX2007012081A (es) 2007-11-21
EA014183B1 (ru) 2010-10-29
EA200702102A1 (ru) 2008-04-28
BRPI0609601A2 (pt) 2010-04-20
SG179459A1 (en) 2012-04-27
US20060222708A1 (en) 2006-10-05
TW200714299A (en) 2007-04-16
AU2006228820A1 (en) 2006-10-05
JP2008534533A (ja) 2008-08-28
DE102005015128A1 (de) 2006-10-05
SV2008002466A (es) 2008-02-08
NO20075404L (no) 2007-12-20
JP2013155190A (ja) 2013-08-15
IL186081A0 (en) 2008-01-20
WO2006102990A3 (de) 2007-03-22
DE102005015128B4 (de) 2008-12-11
JP5843416B2 (ja) 2016-01-13
CN101132766A (zh) 2008-02-27
US9763960B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
GT200600126A (es) Oblea que contiene hormonas estoides
UY30109A1 (es) Formas farmacológicas en forma de película para usar en la cavidad bucal (obleas)
BRPI0819235A2 (pt) Sistema de distribuição transdérmica para hormônios e esteróides
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CR10612A (es) Anticuerpo especifico prlr y sus usos
CR9033A (es) Agentes de transportes derivados cupredoxin y metodos para uso
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
CL2017001952A1 (es) Composiciones estables de povidona-yodo con esteroides o antiinflamatorios no esteroideos (divisional solicitud 592-2014)
AR067441A1 (es) Aromatizador de ambiente con apoyo
CR9763A (es) Uso de una sola dosis de moleculas de union especificas cd20
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
PL2179100T3 (pl) Płuczka WC z przesuniętym w czasie uwalnianiem dwóch substancji biologicznie aktywnych
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
AR066527A1 (es) Panel para la contruccion de edificios con salientes perpendiculares a una cara
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
ECSP055888A (es) Derivados de aril-quinazolin/aril-2-amino-fenil metanona que promueven la liberación de la hormona paratiroides.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CL2009001342A1 (es) Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c; preparados farmaceuticos que lo contienen; compuesto 11 alfa-hidroxi-15 beta, 16 beta-metilen-androst-4-en-3,17-diona; procedimiento para preparar dicho compuesto que comprende el uso de microorganismos.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CR8300S (es) Recipiente para ajo